

Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

NCT06923072

Status	RECRUITING
Phase	Phase 2
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (8)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
 - Provision of signed and dated informed consent form by the subject or Legally Authorized Representative (LAR).
 - Stated willingness to comply with all study procedures and availability for the duration of the study.
 - Male or female, aged 18 or older.
 - Subjects diagnosed with systemic Degos disease, who manifest neurologic abnormalities observed clinically, radiologically or in abnormal laboratory findings.
- ... and 3 more (see full listing online)

Exclusion (16)

- Active infection not responding to appropriate therapy
 - Hemoglobin ≤ 7 g/dL
 - Platelet counts ≤ 50 K /mCL
 - Neutropenia (ANC ≤ 0.5 x k/mCL)
 - Lymphopenia (Absolute Lymphocyte Count ≤ 0.2 x k/mCL)
- ... and 11 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States